What’s Altimmune Inc. (ALT)’s Price to Earnings Ratio?


Altimmune Inc. (NASDAQ:ALT) saw a downside of -2.06% to $14.52 after subtracting -$0.3 on Wednesday. The 5-day average trading volume is 2,395,517 shares of the company’s common stock. It has gained $15.77 in the past week and touched a new high 3 times within the past 5 days. An average of 1,844,384 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,373,930.

ALT’s 1-month performance is 63.04% or $5.26 on its low of $8.98 reached on 11/29/22. The company’s shares have touched a 52-week low of $3.83 and high of $23.49, with the stock’s rally to the 52-week high happening on 09/02/22. YTD, ALT has achieved 61.79% or $5.15 and has reached a new high 19 times. However, the current price is down -38.21% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

ALT stock investors last saw insider trading activity on Dec 22.Pisano Wayne (Director) most recently sold 20,000 shares at $15.01 per share on Dec 22. This transaction cost the insider $300,268. President and CEO, Garg Vipin K, sold 20,000 shares at a price of $20.02 on Aug 31. Then, on Aug 12, President and CEO Garg Vipin K sold 15,000 shares at a price of $15.06 per share. This transaction amounted to $225,890.

Valuation Metrics

ALT stock has a beta of 0.16. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 225.53 while the price-to-book (PB) in the most recent quarter is 3.56.

Altimmune Inc.’s quick ratio for the period ended June 29 was 13.40, with the current ratio over the same period at 13.40. The firm’s gross profit as reported stood at $101.32 million against revenue of $4.41 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Altimmune Inc.’s cash and short-term investments amounted to $74.36 million against total debt of $1.33 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -42.47% to -$23.52 million, while revenue of -$20.11 million was 14.5% off the previous quarter. Analysts expected ALT to announce -$0.47 per share in earnings in its latest quarter, but it posted -$0.42, representing a 10.60% surprise. EBITDA for the quarter stood at more than -$24.89 million. ALT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 20.25 million, with total debt at $1.33 million. Shareholders hold equity totaling $49.16 million.

Let’s look briefly at Altimmune Inc. (ALT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 27 December was 64.80% to suggest the stock is trending Neutral, with historical volatility in this time period at 153.31%.

The stock’s 5-day moving average is $14.96, reflecting a +20.25% or $2.41 change from its current price. ALT is currently trading +51.27% above its 20-day SMA, +15.40% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +33.74% and SMA200 by+122.55%.

Stochastic %K and %D was 85.61% and 90.63% and the average true range (ATR) pointed at 1.30. The RSI (14) points at 63.52%, while the 14-day stochastic is at 77.91% with the period’s ATR at 1.19. The stock’s 9-day MACD Oscillator is pointing at 1.61 and 2.57 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Altimmune Inc. (NASDAQ: ALT), Goldman launched coverage with a Buy rating. Analysts offering their rating for ALT stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ALT as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.

What is ALT’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $14.00 and a high of $50.00, with their median price target at $26.00. Looking at these predictions, the average price target given by analysts is for Altimmune Inc. (ALT) stock is $27.75.


Please enter your comment!
Please enter your name here